ImmuCell Corporation
ICCC
$5.19
$0.122.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 52.10% | 11.40% | 54.92% | 110.58% | 30.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.10% | 11.40% | 54.92% | 110.58% | 30.30% |
| Cost of Revenue | 36.28% | 7.23% | 70.46% | 57.74% | 42.13% |
| Gross Profit | 81.46% | 25.00% | 17.88% | 663.10% | 12.87% |
| SG&A Expenses | 16.41% | 2.99% | 27.05% | -7.85% | -24.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.64% | 0.09% | 41.81% | 32.53% | 12.45% |
| Operating Income | 315.82% | 51.44% | -6.29% | 86.70% | 54.39% |
| Income Before Tax | 145.73% | 25.47% | -11.04% | 81.13% | 31.68% |
| Income Tax Expenses | 361.54% | 550.00% | -13.33% | -13.33% | -13.33% |
| Earnings from Continuing Operations | 145.15% | 25.35% | -11.01% | 81.09% | 31.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 145.15% | 25.35% | -11.01% | 81.09% | 31.66% |
| EBIT | 315.82% | 51.44% | -6.29% | 86.70% | 54.39% |
| EBITDA | 757.96% | 120.72% | -15.48% | 122.96% | 145.04% |
| EPS Basic | 139.16% | 29.18% | -10.11% | 81.09% | 31.68% |
| Normalized Basic EPS | 231.64% | 49.10% | -9.08% | 81.08% | 43.07% |
| EPS Diluted | 138.40% | 25.80% | -11.11% | 80.00% | 30.33% |
| Normalized Diluted EPS | 231.64% | 49.10% | -9.08% | 81.08% | 43.07% |
| Average Basic Shares Outstanding | 15.29% | 5.39% | 0.81% | 0.05% | 0.04% |
| Average Diluted Shares Outstanding | 15.29% | 5.39% | 0.81% | 0.05% | 0.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |